Berriman is already chairman of ReNeuron Group, Autifony Therapeutics and Depixus as well as non-executive director of Autolus. In the past, he has served as chairman of Heptares Therapeutics and Algeta and was a director of Micromet until its sale to Amgen. He was director of Abingworth Management, and before that, spent 14 years with Celltech Group.

Berriman has a degree in Chemical Engineering from the University of Cambridge and an MBA from the London Business School.